Unknown

Dataset Information

Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?


ABSTRACT: During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells. Initially, neoantigens were not recognized as preferred targets for cancer immunotherapy due to their enormous diversity and the therefore limited options to develop "one fits all" pharmacologic solutions. In recent years, the experience obtained in clinical trials demonstrating a predictive role of neoantigens in checkpoint inhibition has changed our view on the clinical potential of neoantigens in cancer immunotherapy. Technological advances such as sequencing of whole cancer genomes, the development of reliable algorithms for epitope prediction, and an increasing number of immunotherapeutic options now facilitate the d

SUBMITTER: Wirth TC 

PROVIDER: S-EPMC5742119 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature